Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHEK2 Founder Variants and Thyroid Cancer Risk.

Thyroid : official journal of the American Thyroid Association - 1 Apr 2024

Brock Pamela, Liynarachchi Sandya, Nieminen Taina T, Chan Carlos, Kohlmann Wendy, Stout Leigh Anne, Yao Song, La Greca Amanda, Jensen Kirk E, Kolesar Jill M, Salhia Bodour, Gulhati Pat, Hicks J Kevin, Ringel Matthew D

Abstract excerpt

Background: Germline pathogenic variants in CHEK2 are associated with a moderate increase in the lifetime risk for breast cancer. Increased risk for other cancers, including non-medullary thyroid cancer (NMTC), has also been suggested. To date, data implicating CHEK2 variants in NMTC predisposition primarily derive from studies within Poland, driven by a splice site variant (c.444 + 1G>A) that is uncommon in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Case-Control Studies
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Germ-Line Mutation

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38279823
DOI: 10.1089/thy.2023.0529
PMCID: PMC10998703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHEK2 Founder Variants and Thyroid Cancer Risk.PMID 38279823Read ↗

A Germline CHEK2 Mutation in a Family with Papillary Thyroid Cancer.Semantic proximity Read ↗

Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer.Semantic proximity Read ↗

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Semantic proximity Read ↗

CHEK2 mutations and the risk of papillary thyroid cancer.Semantic proximity Read ↗

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.Semantic proximity Read ↗

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.Semantic proximity Read ↗

Identification of Rare Variants Predisposing to Thyroid CancerSemantic proximity Read ↗

Beyond 1100delC: distinct CHEK2 variants and unique cancer phenotypes in Northeast Brazil.Semantic proximity Read ↗

Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.Semantic proximity Read ↗

Genetic predisposition to differentiated thyroid cancer in the Polish population.Semantic proximity Read ↗

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.Semantic proximity Read ↗

Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.